Form 4: Apellis Director Keli Walbert Receives Equity Awards

Apellis Pharmaceuticals director Keli Walbert was granted 7,961 restricted stock units and 14,684 stock options effective January 1, 2026.

Summary

• Director Keli Walbert of Apellis Pharmaceuticals, Inc. was granted equity awards.
• The awards include 7,961 restricted stock units (RSUs) and 14,684 stock options.
• The effective date of these transactions is January 1, 2026.
• The RSUs were granted at a price of $0 and will fully vest on the first anniversary of the grant date, contingent on continued service as a director.
• The stock options have an exercise price of $25.12 and were granted at a price of $0.
• The stock options vest quarterly on the last day of each quarter from the grant date, subject to continued service, and expire on December 31, 2033.
• Following these transactions, Keli Walbert beneficially owns 17,051 shares of common stock directly and 14,684 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation filing for a director, which is generally seen as a positive for aligning interests, but does not contain new operational or financial news that would significantly alter the company's outlook.

Positives

• The grant of equity awards to a director aligns their interests with shareholders, promoting long-term value creation.
• The vesting schedules for both RSUs and stock options are tied to continued service, encouraging sustained commitment to the company.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend into the future, indicating a long-term incentive structure designed to retain the director and align their interests with the company's sustained performance.

Industry Context

Routine equity grants to directors are a standard practice in the pharmaceutical and biotechnology industry. This compensation mechanism is widely used to attract and retain qualified board members, aligning their financial interests with the long-term success and shareholder value of the company.

Comparison to Industry Standards

• Granting equity awards, including restricted stock units and stock options, to non-employee directors is a common compensation practice across publicly traded companies, particularly prevalent in the pharmaceutical sector.
• The vesting schedules tied to continued service are standard for director compensation, similar to practices observed at comparable companies like Biogen or Moderna, ensuring long-term commitment and oversight.
• The exercise price of $25.12 for the options would typically correspond to the closing price of APLS stock on the grant date, which is a standard methodology for establishing the strike price of incentive stock options.

Related Party Transactions

• The equity grants to Director Keli Walbert represent compensation to an insider, which is a common form of related party transaction in corporate governance.

Stakeholder Impact

• Shareholders: The grant of equity awards aligns the director's interests with shareholders, potentially encouraging decisions that benefit long-term stock performance. This also represents a minor potential for future dilution upon vesting and exercise.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The 7,961 restricted stock units will fully vest on January 1, 2027, subject to continued service as a director.
• The 14,684 stock options will vest quarterly from January 1, 2026, subject to continued service, until their expiration on December 31, 2033.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director and does not contain information that would warrant a change in investment recommendation. It is a standard disclosure of insider activity, not indicative of operational performance, strategic shifts, or material financial changes that would impact the company's valuation.

Keywords

Apellis Pharmaceuticals, APLS, Keli Walbert, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership